Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms CONQUER
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 03 May 2023 Results of post hoc analysis (n=3348) assessing at population and individual patient levels, the sustained response of reduction in migraine headache days in patients with migraine treated with galcanezumab from two 6-month episodic migraine (EM; EVOLVE-1/EVOLVE-2), one 3-month chronic migraine (CM; REGAIN), and one 3-month treatment-resistant migraine (CONQUER) studies, published in the Headache.
  • 27 Apr 2023 Results of pooled analysis(n=1551 from 3 studies EVOLVE-1, EVOLVE-2, and CONQUER ) assessing Clinically meaningful improvement in disability (MIDAS score) in the absence of greater than 50% reductions in monthly migraine days with galcanezumab presented at the 75th Annual Meeting of the American Academy of Neurology 2023
  • 16 Feb 2023 Results of post hoc analysis assessing changes in interictal burden with galcanezumab versus placebo in patients with episodic (EM) or chronic migraine published in the Headache

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top